Pomalyst Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients in Phase 3 Trial
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…